Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial


SHITARA K., Ozguroglu M. , BANG Y., DI BARTOLOMEO M., MANDALA M., RYU M., ...Daha Fazla

LANCET, cilt.392, ss.123-133, 2018 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 392 Konu: 10142
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1016/s0140-6736(18)31257-1
  • Dergi Adı: LANCET
  • Sayfa Sayıları: ss.123-133

Özet

Background Patients with advanced gastric or gastro-oesophageal junction cancer that progresses on chemotherapy have poor outcomes. We compared pembrolizumab with paclitaxel in patients with advanced gastric or gastrooesophageal junction cancer that progressed on first-line chemotherapy with a platinum and fluoropyrimidine.